Zoetis Inc. $ZTS Shares Acquired by Evergreen Capital Management LLC

Evergreen Capital Management LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 31.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,106 shares of the company’s stock after acquiring an additional 749 shares during the period. Evergreen Capital Management LLC’s holdings in Zoetis were worth $511,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Nuveen LLC purchased a new stake in Zoetis during the 1st quarter worth about $616,375,000. Sarasin & Partners LLP purchased a new stake in Zoetis during the 1st quarter worth about $339,111,000. Mackenzie Financial Corp lifted its holdings in Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after buying an additional 1,782,110 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Zoetis by 14,731.3% during the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company’s stock worth $289,666,000 after buying an additional 1,747,423 shares during the last quarter. Finally, Polen Capital Management LLC lifted its holdings in Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ZTS shares. UBS Group decreased their price target on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $202.43.

Zoetis Price Performance

Shares of ZTS opened at $156.45 on Tuesday. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a market capitalization of $69.34 billion, a price-to-earnings ratio of 26.93, a price-to-earnings-growth ratio of 2.51 and a beta of 0.88. The firm has a 50-day simple moving average of $153.49 and a 200-day simple moving average of $157.85. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the prior year, the firm earned $1.56 earnings per share. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.